Panacea Biotec Ltd

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live

Panacea Biotec that the Central Medical Services Society, Ministry of Health and Family Welfare, Government of India (CMSS) has, vide its Letter of Acceptance (LOA) dated 08 October 2025, accepted the Company's offer for supply of bivalent oral polio vaccine (bOPV) against the tender issued by it in this regard. As per the LOA, the Company will supply the vaccine worth Rs.127.20 crore in several tranches over a period of 90 - 480 days from the date of issuance of LOA. Powered by Capital Market - Live

The order, valued at Rs 127.20 crore, will be executed in multiple tranches over a period of 90 to 480 days from the date of issuance of the letter of acceptance (LOA). The contract has been awarded by a domestic entity, and there is no interest of the promoter, promoter group, or group companies in the awarding entity. The transaction does not fall under related party transactions. Panacea Biotec is one of India's leading research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets. The company reported consolidated net profit of Rs 4.05 crore in Q1 FY26 as against net loss of Rs 15.80 crore in Q1 FY25. Revenue from operations jumped 44.1% year on year to Rs 166.70 crore in Q1 FY26. Powered by Capital Market - Live

Panacea Biotec announced that the Central Medical Services Society, Ministry of Health and Family Welfare, Government of India ('CMSS') has, vide its Letter of Acceptance (LOA) dated 08 October 2025, accepted the Company's offer for supply of bivalent oral polio vaccine (bOPV) against the tender issued by it in this regard. As per the LOA, the Company will supply the vaccine worth Rs.127.20 crore in several tranches over a period of 90 - 480 days from the date of issuance of LOA. Powered by Capital Market - Live

Panacea Biotec has received a Letter of Award from UNICEF for a Long-Term Agreement for supply of bivalent oral polio vaccine (bOPV) to UNICEF starting from 1st April 2026 to 31st March 2030. The total award to the Company is for supply of bOPV in 10 and 20 vial presentation worth ~US$ 35.65 million (~Rs.315 crore) for a period of Q2 CY2026 and CY2027. Powered by Capital Market - Live

The company will supply vaccine in 10 and 20 vial presentations during Q2 CY2026 and CY2027, under an order worth $35.65 million (around Rs 315 crore). Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets. The company reported a consolidated net profit of Rs 4.05 crore in Q1 FY26 compared with net loss of Rs 15.80 crore in Q1 FY25. Net sales jumped 44.1% YoY to Rs 166.70 crore in Q1 FY26.Powered by Capital Market - Live

Panacea Biotec announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live

Net profit of Panacea Biotec reported to Rs 4.05 crore in the quarter ended June 2025 as against net loss of Rs 15.80 crore during the previous quarter ended June 2024. Sales rose 44.05% to Rs 166.70 crore in the quarter ended June 2025 as against Rs 115.72 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales166.70115.72 44 OPM %-0.71-12.09 - PBDT3.63-11.06 LP PBT-4.76-19.79 76 NP4.05-15.80 LP Powered by Capital Market - Live

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 August 2025.Powered by Capital Market - Live

Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects. EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8'C and maintains stability for over 2-years under recommended conditions. On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, 'It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.' Powered by Capital Market - Live